In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flexion Exploits Big Pharma as Discovery Supplier

Executive Summary

Big Pharma, unable to exploit its own research productivity, is increasingly seeing itself as a supplier of discovery assets. That's bad news for discovery-based biotech, but good news for companies with a talent for faster, more predictable development capabilities. Since its formation in the fall of 2007, Flexion Therapeutics has apparently had no trouble getting Big Pharmas to let them review their shelved compounds, 130 or so of them from eight to 10 companies. Flexion, built around Lilly's fast-to-proof-of-concept strategy, is attempting to take advantage of the trend; it's in-licensed five products from three Big Pharmas.
Advertisement

Related Content

Reinventing Flexion For The World Beyond Proof-Of-Concept
Financings of the Fortnight Comes Bearing Gifts
No Longer Aiming To Partner At Proof-of-Concept, Flexion Raises $20M For Late-Stage Trials
With Pharma Ready to Pare Portfolios, Project Financing Funds Make Their Pitches
Lilly Tries to Buy Time
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Lilly and Merck Lead the Way With Asian FIPNet Strategies
Flexion: The In-Licensing Advantage of Cheap Proof-of-Concept
Lilly's Chorus Experiment
Lilly's Chorus Experiment

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel